Goldman Sachs: Gives Gilead (GILD.US) a "neutral" rating, long-term HIV therapy sees major opportunity.

Smart Financial APP learned that Goldman Sachs released a research report, giving Gilead Sciences (GILD.US) a "neutral" rating with a target price of $100.